MARKET

ARQL

ARQL

ArQule
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.89
+0.19
+2.47%
After Hours: 7.89 0 0.00% 17:02 11/12 EST
OPEN
7.70
PREV CLOSE
7.70
HIGH
7.97
LOW
7.67
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
12.22
52 WEEK LOW
2.230
MARKET CAP
952.59M
P/E (TTM)
-22.9427
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARQL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARQL News

  • ArQule down 17% on early-stage data on ARQ 531
  • seekingalpha.6d ago
  • Here's Why ArQule Fell as Much as 28.3% Today
  • MotleyFool.com.6d ago
  • ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
  • Business Wire.6d ago
  • Benzinga's Top Upgrades, Downgrades For November 5, 2019
  • Benzinga.11/05 15:00

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About ARQL

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
More

Webull offers ArQule, Inc. (ARQL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.